The SynGen Management Team includes:
- William Gerber, MD, President and CEO
- Philip H. Coelho, CTO and Co-Founder
- Chuck Novak, Vice President and Chief Financial Officer
- David Hodl, President, Cell Processing SBU
- Paul Hoseit, Senior Vice President, Research and Development
William Gerber, MD was an Investment Partner with Bay City Capital from 2005 to 2013, and he remains an active advisor to the firm. Prior to his role with Bay City Capital, he was President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber also served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Nabsys and Omicia. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.
Philip H. Coelho
Chief Technology Officer and Co-Founder
Philip H. Coelho, Chief Technology Officer and Co-Founder of SynGen Inc., is an engineer / inventor who has been awarded more that 30 U.S. patents related to cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis.
During his tenure as Founder, Chairman and CEO of Thermogenesis Corp (NASDAQ: KOOL), Mr. Coelho developed the Thermoline ultra rapid blood plasma freezers and thawers, the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood, the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood and the AutoXpress System, which automates the sterile harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive and AutoXpress Systems have defined cGMP standards in cord blood processing and banking worldwide.
In 2002, Mr. Coelho initiated an effort to obtain federal funding sufficient to allow qualified public cord blood banks to build a substantial inventory of ethnically diverse, clinical grade, cord blood stem cell units for all patients in need. Passed unanimously by Congress and signed by President Bush on December 19, 2005 the “Stem Cell Therapeutic and Research Act of 2005” authorized and began financing of a national inventory of 150,000 units of cryopreserved, HLA typed, cord blood stem cells and a website that allowed transplant physicians to choose optimal stem cell units for the treatment of blood cancers such as leukemia, myeloma, and lymphoma; inherited immunodeficiencies and marrow failure disorders and inherited disorders or errors of metabolism. During this last decade, Mr. Coelho gathered detailed knowledge of the practices of the major public and private cord blood banks in 30 countries and has working relationships with many scientists, clinicians and directors associated with these cord blood banks.
Currently Mr. Coelho, as CTO of SynGen Inc., is leading the development of new products for the clinical and research fields that improve the speed and efficiency of harvesting target cell populations resident within peripheral or placental/cord blood or bone marrow and washing/purifying ex-vivo expanded cell populations derived from those cells.
Chuck Novak brings more than 40 years of financial management experience to the SynGen team. His most recent experience before joining SynGen brought financial stability to ConQuip, Inc. where he was a Director, Shareholder, Corporate Secretary and CFO. While in this position, he was recognized by the Sacramento Business Journal as their 2014 CFO of the year in the small business category. Chuck has more than 20 years of accounting and financial management experience with Hewlett-Packard and USCS as well as directing HealthTek, Inc., DeScribe,Inc., WebRaiser Technologies, Inc., Integrated Surgical Systems, Inc. and CUREXO Technologies, Inc. as their Chief Financial Officer. Chuck’s diverse experience includes financial, administrative and operational management responsibilities with both small and large companies as well as private and public SEC reporting companies. Chuck earned his Bachelor of Science degree in Accounting from Lewis University, Lockport, Illinois.
David Hodl brings 19 years of experience in product commercialization and business development in the life science and medical products industry to SynGen. During his tenure with BD Technologies, BD’s Corporate Innovation Center, he led the commercialization of several cell-based technologies, including BD FACS CAP™, an antibody-based cell surface marker profiling platform and BD’s Discovery Platform, a custom cell culture environment development service. He also played a leading role in executing the development partnership between BD and Fate Therapeutics to access proprietary technology for developing products for expansion and differentiation of induced pluripotent stem cells. He was also instrumental in assessing opportunities for BD to develop next generation sequencing technologies.
Prior to Becton Dickinson, David held leadership positions in emerging companies focused on pharmacogenomics services and hepatic cell-based products and services. He earned a B.S. in biology from Linfield College and an MBA from North Carolina State University with a focus on technology commercialization.
Paul Hoseit has been developing electronic instrumentation and imaging products for multiple industries and releasing them to the market place for over 29 years. He has over 15 years of medical device product development experience including electronic and embedded software design, program management, and R&D department management. Paul has led the development and release of several intra-vascular imaging and measurement medical devices several of which were major platforms with multiple diagnostic modes. He has been responsible for over 80 technical personnel in a medical device engineering department consisting of various disciplines (Software, Hardware, Signal & Image Processing, Program Management, Systems & Sustaining) with a budget over 13 million. Paul has designed many electronic instruments (analog and digital design) and personally developed embedded and digital signal processing software for real time diagnostic equipment. He has developed product development processes, defined product roadmaps led a quality system implementation and holds 9 patents. Paul has a B.S. Biology, B.S. Electrical Engineering and M.S. Biomedical Engineering.